0.60
+0.0468(+8.46%)
Currency In NOK
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
36
First IPO Date
December 13, 2017
| Name | Title | Pay | Year Born |
| Mr. Oystein Soug M.Sc | Chief Executive Officer | 2.79M | 1969 |
| Ms. Anne Cecile Alvik | Head of Quality Assurance & Employee Representative Director | 1.39M | N/A |
| Mr. Stian Brekke | Head of Regulatory Affairs | 1.45M | N/A |
| Ms. Kristine Lofthus | Chief Production Officer | 1.56M | N/A |
| Mr. Tore Kvam | Chief Financial Officer | 1.86M | N/A |
| Dr. Anne-Kirsti Aksnes Ph.D. | Chief Clinical Officer | 1.98M | N/A |
| Ms. Gro Elisabeth Hjellum | Chief Operating Officer | 2.03M | N/A |
| Dr. Kari Myren M.D. | Chief Medical Officer | 2.17M | N/A |
| Ms. Kaja Tunhovd Johansen | Head of Quality Control | 0 | N/A |
| Ms. Froydis Schulz | Head of Health Safety & Environment | 0 | N/A |
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.